Oruka Therapeutics, Inc. Insider Trading

ORKA

Last 12 months

Insiders sold $338M and bought nothing on the open market.

11% of the selling was scheduled in advance under 10b5-1 plans. Director Tomas Kiselak sold $300M on Jul 1, 49% of their stake, outside a plan. The last open-market buy by an executive or director was in Nov 2021.

Net open-market

−$338M

0 buys · 42 sales

Under a 10b5-1 plan

11%

of the value sold

Insiders who bought / sold

0 / 7

executives and directors

Last open-market buy

Nov 2021

Nov 22, 2021

Get an email when ORKA's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Oct 20	Paul T Quinlan General Counsel	Sold10b5-1 plan 5 parts	9,000	$78.53 average	707K	23%	Form 4
Oct 15	Joana Goncalves Chief Medical Officer	Sold10b5-1 plan 5 parts	7,000	$74.81 average	524K	18%	Form 4
Oct 12	Arjun Agarwal Senior Vice President, Finance	Sold10b5-1 plan 4 parts	9,999	$80.60 average	806K	41%	Form 4
Oct 1	Lawrence Otto Klein Chief Executive Officer	Sold10b5-1 plan 3 parts	25,000	$83.62 average	$2.09M	2.6%	Form 4
Sep 21	Arjun Agarwal Senior Vice President, Finance	Sold10b5-1 plan	533	$95.75	51K	3.6%	Form 4
Sep 21	Paul T Quinlan General Counsel	Sold10b5-1 plan 4 parts	10,000	$93.64 average	936K	25%	Form 4
Sep 15	Joana Goncalves Chief Medical Officer	Sold10b5-1 plan 5 parts	7,947	$92.38 average	734K	20%	Form 4
Sep 11 – 15	Arjun Agarwal Senior Vice President, Finance	Sold10b5-1 plan 5 parts	10,019	$92.42 average	926K	40%	Form 4
Sep 15	Lawrence Otto Klein Chief Executive Officer	SoldNo plan	2,452	$95.71	235K	0.3%	Form 4
Sep 15	Paul T Quinlan General Counsel	SoldNo plan	1,039	$95.71	99K	3.3%	Form 4
Sep 15	Laura Lee Sandler Chief Operating Officer	SoldNo plan	906	$95.71	87K	0.4%	Form 4
Sep 1	Laura Lee Sandler Chief Operating Officer	Sold10b5-1 plan 2 parts	5,000	$91.82 average	459K	2.1%	Form 4
Sep 1	Lawrence Otto Klein Chief Executive Officer	Sold10b5-1 plan 3 parts	75,000	$91.84 average	$6.89M	7.5%	Form 4
Aug 17	Joana Goncalves Chief Medical Officer	Sold10b5-1 plan 4 parts	7,000	$111.84 average	783K	18%	Form 4
Aug 14	Paul T Quinlan General Counsel	Sold10b5-1 plan 6 parts	52,000	$108.49 average	$5.64M	63%	Form 4
Aug 13	Arjun Agarwal Senior Vice President, Finance	Sold10b5-1 plan 5 parts	10,000	$106.66 average	$1.07M	40%	Form 4
Jul 15	Joana Goncalves Chief Medical Officer	Sold10b5-1 plan 4 parts	7,000	$86.28 average	604K	18%	Form 4
Jul 13	Arjun Agarwal Senior Vice President, Finance	Sold10b5-1 plan 4 parts	9,999	$84.63 average	846K	40%	Form 4
Jul 1	Tomas Kiselak Director	SoldNo plan	3,553,410	$84.43	$300M	49%	Form 4
Jul 1	Laura Lee Sandler Chief Operating Officer	Sold10b5-1 plan 3 parts	5,000	$94.42 average	472K	2.1%	Form 4
Jun 22	Arjun Agarwal Senior Vice President, Finance	Sold10b5-1 plan 2 parts	1,587	$80.95 average	128K	9.4%	Form 4
Jun 12 – 15	Arjun Agarwal Senior Vice President, Finance	Sold10b5-1 plan 4 parts	9,854	$69.72 average	687K	37%	Form 4
Jun 15	Joana Goncalves Chief Medical Officer	Sold10b5-1 plan 4 parts	7,947	$69.28 average	551K	20%	Form 4
Jun 15	Lawrence Otto Klein Chief Executive Officer	SoldNo plan	1,729	$69.69	120K	0.2%	Form 4
Jun 15	Laura Lee Sandler Chief Operating Officer	SoldNo plan	600	$69.69	42K	0.3%	Form 4
Jun 15	Paul T Quinlan General Counsel	SoldNo plan	733	$69.69	51K	2.3%	Form 4
Jun 11 – 12	Carl Dambkowski Director	Sold10b5-1 plan 2 parts	35,000	$70.12 average	$2.45M	47%	Form 4
May 21	Carl Dambkowski Director	Sold10b5-1 plan 3 parts	105,000	$58.97 average	$6.19M	59%	Form 4
May 18	Arjun Agarwal Senior Vice President, Finance	Sold10b5-1 plan 4 parts	10,290	$59.07 average	608K	39%	Form 4
May 15	Joana Goncalves Chief Medical Officer	Sold10b5-1 plan 3 parts	7,000	$61.85 average	433K	17%	Form 4
May 1	Laura Lee Sandler Chief Operating Officer	Sold10b5-1 plan 6 parts	5,000	$63.88 average	319K	2.1%	Form 4
Apr 15	Joana Goncalves Chief Medical Officer	Sold10b5-1 plan 3 parts	7,000	$66.12 average	463K	17%	Form 4
Mar 16	Lawrence Otto Klein Chief Executive Officer	SoldNo plan	1,729	$41.30	71K	0.2%	Form 4
Mar 16	Arjun Agarwal Senior Vice President, Finance	SoldNo plan	395	$41.30	16K	2.1%	Form 4
Mar 16	Laura Lee Sandler Chief Operating Officer	SoldNo plan	600	$41.30	25K	0.3%	Form 4
Mar 16	Joana Goncalves Chief Medical Officer	Sold10b5-1 plan 4 parts	7,641	$40.91 average	313K	19%	Form 4
Mar 16	Paul T Quinlan General Counsel	SoldNo plan	733	$41.30	30K	2.3%	Form 4
Mar 2	Laura Lee Sandler Chief Operating Officer	Sold10b5-1 plan 2 parts	5,000	$33.56 average	168K	2.1%	Form 4
Feb 17	Joana Goncalves Chief Medical Officer	Sold10b5-1 plan 2 parts	7,000	$32.36 average	227K	17%	Form 4
Jan 15	Joana Goncalves Chief Medical Officer	Sold10b5-1 plan 2 parts	7,000	$31.81 average	223K	82%	Form 4

Oct 2010b5-1 plan
Paul T Quinlan
General Counsel · sold 9,000 at avg $78.53
707K
23% of stake
Oct 1510b5-1 plan
Joana Goncalves
Chief Medical Officer · sold 7,000 at avg $74.81
524K
18% of stake
Oct 1210b5-1 plan
Arjun Agarwal
Senior Vice President, Finance · sold 9,999 at avg $80.60
806K
41% of stake
Oct 110b5-1 plan
Lawrence Otto Klein
Chief Executive Officer · sold 25,000 at avg $83.62
$2.09M
2.6% of stake
Sep 2110b5-1 plan
Arjun Agarwal
Senior Vice President, Finance · sold 533 at $95.75
51K
3.6% of stake
Sep 2110b5-1 plan
Paul T Quinlan
General Counsel · sold 10,000 at avg $93.64
936K
25% of stake
Sep 1510b5-1 plan
Joana Goncalves
Chief Medical Officer · sold 7,947 at avg $92.38
734K
20% of stake
Sep 11 – 1510b5-1 plan
Arjun Agarwal
Senior Vice President, Finance · sold 10,019 at avg $92.42
926K
40% of stake
Sep 15No plan
Lawrence Otto Klein
Chief Executive Officer · sold 2,452 at $95.71
235K
0.3% of stake
Sep 15No plan
Paul T Quinlan
General Counsel · sold 1,039 at $95.71
99K
3.3% of stake
Sep 15No plan
Laura Lee Sandler
Chief Operating Officer · sold 906 at $95.71
87K
0.4% of stake
Sep 110b5-1 plan
Laura Lee Sandler
Chief Operating Officer · sold 5,000 at avg $91.82
459K
2.1% of stake
Sep 110b5-1 plan
Lawrence Otto Klein
Chief Executive Officer · sold 75,000 at avg $91.84
$6.89M
7.5% of stake
Aug 1710b5-1 plan
Joana Goncalves
Chief Medical Officer · sold 7,000 at avg $111.84
783K
18% of stake
Aug 1410b5-1 plan
Paul T Quinlan
General Counsel · sold 52,000 at avg $108.49
$5.64M
63% of stake
Aug 1310b5-1 plan
Arjun Agarwal
Senior Vice President, Finance · sold 10,000 at avg $106.66
$1.07M
40% of stake
Jul 1510b5-1 plan
Joana Goncalves
Chief Medical Officer · sold 7,000 at avg $86.28
604K
18% of stake
Jul 1310b5-1 plan
Arjun Agarwal
Senior Vice President, Finance · sold 9,999 at avg $84.63
846K
40% of stake
Jul 1No plan
Tomas Kiselak
Director · sold 3,553,410 at $84.43
$300M
49% of stake
Jul 110b5-1 plan
Laura Lee Sandler
Chief Operating Officer · sold 5,000 at avg $94.42
472K
2.1% of stake
Jun 2210b5-1 plan
Arjun Agarwal
Senior Vice President, Finance · sold 1,587 at avg $80.95
128K
9.4% of stake
Jun 12 – 1510b5-1 plan
Arjun Agarwal
Senior Vice President, Finance · sold 9,854 at avg $69.72
687K
37% of stake
Jun 1510b5-1 plan
Joana Goncalves
Chief Medical Officer · sold 7,947 at avg $69.28
551K
20% of stake
Jun 15No plan
Lawrence Otto Klein
Chief Executive Officer · sold 1,729 at $69.69
120K
0.2% of stake
Jun 15No plan
Laura Lee Sandler
Chief Operating Officer · sold 600 at $69.69
42K
0.3% of stake
Jun 15No plan
Paul T Quinlan
General Counsel · sold 733 at $69.69
51K
2.3% of stake
Jun 11 – 1210b5-1 plan
Carl Dambkowski
Director · sold 35,000 at avg $70.12
$2.45M
47% of stake
May 2110b5-1 plan
Carl Dambkowski
Director · sold 105,000 at avg $58.97
$6.19M
59% of stake
May 1810b5-1 plan
Arjun Agarwal
Senior Vice President, Finance · sold 10,290 at avg $59.07
608K
39% of stake
May 1510b5-1 plan
Joana Goncalves
Chief Medical Officer · sold 7,000 at avg $61.85
433K
17% of stake
May 110b5-1 plan
Laura Lee Sandler
Chief Operating Officer · sold 5,000 at avg $63.88
319K
2.1% of stake
Apr 1510b5-1 plan
Joana Goncalves
Chief Medical Officer · sold 7,000 at avg $66.12
463K
17% of stake
Mar 16No plan
Lawrence Otto Klein
Chief Executive Officer · sold 1,729 at $41.30
71K
0.2% of stake
Mar 16No plan
Arjun Agarwal
Senior Vice President, Finance · sold 395 at $41.30
16K
2.1% of stake
Mar 16No plan
Laura Lee Sandler
Chief Operating Officer · sold 600 at $41.30
25K
0.3% of stake
Mar 1610b5-1 plan
Joana Goncalves
Chief Medical Officer · sold 7,641 at avg $40.91
313K
19% of stake
Mar 16No plan
Paul T Quinlan
General Counsel · sold 733 at $41.30
30K
2.3% of stake
Mar 210b5-1 plan
Laura Lee Sandler
Chief Operating Officer · sold 5,000 at avg $33.56
168K
2.1% of stake
Feb 1710b5-1 plan
Joana Goncalves
Chief Medical Officer · sold 7,000 at avg $32.36
227K
17% of stake
Jan 1510b5-1 plan
Joana Goncalves
Chief Medical Officer · sold 7,000 at avg $31.81
223K
82% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch ORKA, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with ORKA

CompareIntrinsic value

NKTXNkarta Inc.

$1.56-6.02%10

TNXPTonix Pharmaceuticals Holding Corp

$5.09-3.60%40

SCYXScynexis, Inc.

$3.72-3.63%40

HROWHarrow Inc.

$28.24-5.84%46

HRTXHeron Therapeutics Inc.

$0.28-3.45%36

RCKTRocket Pharmaceuticals Inc.

$2.44-3.94%10

BBIOBridgeBio Pharma, Inc.

$74.95+5.97%30

LGNDLigand Pharmaceuticals Inc.

$322.75+1.71%36

Held by ETFs

ORKA is in 63 US ETFs. The largest of them, with ORKA's weight in each:

Spot a number that looks wrong? Check it in ORKA's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing ORKA

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.